Proactive Investors - Run By Investors For Investors

Lipocine's LPCN 1111 Phase 2b clinical study kicks off

The first patient has been dosed in Lipocene's Phase 2b clinical study for LPCN 1111, its novel testosterone replacement therapy product candidate.
Lipocine's LPCN 1111 Phase 2b clinical study kicks off
LPCN 1111 is a follow-on product candidate to LPCN 1021

The first patient has been dosed in Lipocene's (NASDAQ:LPCN) Phase 2b clinical study for LPCN 1111, its novel testosterone replacement therapy product candidate.

The market did not seem pumped up by the news, as the shares shed 3.9% at US$12.42 in early trading.

The primary objectives of the study will be to determine the optimal dose of LPCN 1111, along with the safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses of LPCN 1111 in males suffering a diminished functional activity of the gonads.

"Progress with this product builds on our leadership position in oral testosterone replacement therapy," said Dr Mahesh Patel, president and chief executive officer of Lipocine.

LPCN 1111 is a follow-on product candidate to LPCN 1021, a twice-daily oral testosterone product candidate that is currently under regulatory review with a Food & Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date of June 28, 2016.

 

View full LPCN profile View Profile

Lipocine Inc Timeline

Related Articles

Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use